Loading clinical trials...
Loading clinical trials...
The TNT Protocol: A Phase 2 Study Using Talimogene Laherparepvec,Nivolumab and Trabectedin as First, Second/Third Line Therapy for Advanced Sarcoma, Including Desmoid Tumor and Chordoma
Conditions
Interventions
Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]
Nivolumab IV Soln 100 MG/10ML
+1 more
Locations
1
United States
Sarcoma Oncology Center
Santa Monica, California, United States
Start Date
May 15, 2019
Primary Completion Date
December 31, 2030
Completion Date
July 31, 2031
Last Updated
February 24, 2025
NCT06066138
NCT05039801
NCT04704661
NCT07479732
NCT03715933
NCT07156565
Lead Sponsor
Sarcoma Oncology Research Center, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions